[2014] 1.4.42 Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statin discuss the following possible strategies with them: stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin reducing the dose within the same intensity group changing the statin to a lower intensity group. [2014] 1.4.43 Seek specialist advice about options for treating people at high risk of CVD such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidaemias, and those with CVD, who are intolerant to 3 different statins. Advice can be sought for example, by telephone, virtual clinic or Adherence to statin therapy 1.4.44 Do not offer coenzyme Q10 or vitamin D to increase adherence to statin Fibrates for preventing CVD 1.4.45 Do not routinely offer fibrates for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes. [2014] Nicotinic acid for preventing CVD 1.4.46 Do not offer nicotinic acid (niacin) for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes. [2014] Bile acid sequestrants (anion exchange resins) for preventing CVD 1.4.47 Do not offer a bile acid sequestrant (anion exchange resin) for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes. 